ArticleCell2010
Duchenne muscular dystrophy models show their age.
Article in Cell, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Perturbation of PI3K/Akt signaling affected autophagy modulation in dystrophin-deficient myoblasts.Cell communication and signaling : CCS · 2021Article
- Crosstalk between RyR2 oxidation and phosphorylation contributes to cardiac dysfunction in mice with Duchenne muscular dystrophy.Journal of molecular and cellular cardiology · 2015Article
- Immune-mediated pathology in Duchenne muscular dystrophy.Science translational medicine · 2015Review
- Article
- Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.Current opinion in supportive and palliative care · 2013Review
- Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy.Nature cell biology · 2013Article
- Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Current gene therapy · 2012Review
- Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice.Human molecular genetics · 2011Article
- Animal models of human genetic diseases: do they need to be faithful to be useful?Molecular genetics and genomics : MGG · 2011Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
The lack of appropriate animal models has hampered efforts to develop therapies for Duchenne muscular dystrophy (DMD). A new mouse model lacking both dystrophin and telomerase (Sacco et al., 2010) closely mimics the pathological progression of human DMD and shows that muscle stem cell activity is a key determinant of disease severity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.